CD8A and ovarian carcinoma: The local secretion of PD-1 antibodies reprogrammed the tumor microenvironment, enhanced CD8+ T cell activity, and exhibited manageable toxicity, Apatinib is an anti-angiogenic drug which has been reported to promote CD8 T cells infiltration and this study showed potential of triple therapy in refractory epithelial ovarian cancer in patients (135).